Skip to content

Electromagnetic fields for drug-resistant cystitis

Effectiveness of modulated extremely low frequency electromagnetic fields compared to placebo in the management of Chronic drug-resistant E. Coli-induced cystitis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20211022052833N3
Enrollment
148
Registered
2024-02-09
Start date
2024-02-15
Completion date
Unknown
Last updated
2024-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic drug-resistant E. Coli cystitis. Interstitial cystitis (chronic)

Interventions

Intervention 1: Intervention group: Experimental group will receive electromagnetic fields, modulated at extremely low frequencies . For treatment, a sequence of signals (BSB) will be created. In orde

Sponsors

CRESO S.r.l.
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Women, age 18 to 80 years, Women suffering from chronic E-coli indued drug-resistant cystitis. Chronic cystitis will be defined as at least 3 episodes of cystitis per year. The women with chronic cystitis will be labelled as drug-resistant if they have previously used six types of antibiotics (trimethoprim, nitrofurantoin, fluoroquinolones, sulfonamides, amoxicillin, and ampicillin) for at least 2 months without satisfactory clinical response.

Exclusion criteria

Exclusion criteria: History of myocardial infarction Stroke Uncontrolled diabetes Cancer Allergic skin reactions Any other condition that can affect participation in the trial

Design outcomes

Primary

MeasureTime frame
Detecting E. coli levels greater than 100,000 CFU/ml. Timepoint: Pre and post-treatment (1 month). Method of measurement: Urine analysis and Urine culture: Urine analysis will be conducted using refractometric and cytofluorimetric methods following SIBioC guidelines, and urine culture will be performed using a conventional method according to AMCLI and EUCAST guidelines.

Countries

Italy

Contacts

Public ContactIvan D'Agostino

ID Medical

drivandagostino@gmail.com+39 388 697 1279

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026